

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/CE4CF8E6D9D4EN.html>

Date: August 2022

Pages: 54

Price: US\$ 3,500.00 (Single User License)

ID: CE4CF8E6D9D4EN

Abstracts

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Collagenase 3 - Drugs In Development, 2022'; Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.

The report 'Collagenase 3 - Drugs In Development, 2022' outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease, Oncology, Respiratory and Toxicology which include indications Osteoarthritis, Osteoarthritis Pain, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chemotherapy Induced Peripheral Neuropathy, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Edema, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome), Multiple Myeloma (Kahler Disease), Myocardial Infarction and Seasonal Allergic Rhinitis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)

The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects

The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies
Involved in Therapeutics Development

Aquilus Pharmaceuticals Inc

Avantyx Pharmaceuticals LLC

Paradigm Biopharmaceuticals Ltd

Pharmahungary Group

SteroTherapeutics LLC

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles

Antisense RNAi Oligonucleotides to Inhibit MMP-13 for Osteoarthritis - Drug Profile

Product Description

Mechanism Of Action

Drug to Inhibit MMP-13 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile

Product Description

Mechanism Of Action

History of Events

Matrix Metalloproteinase 13 (MMP-13) Inhibitors - Drug Profile

Product Description

Mechanism Of Action

History of Events

pentosan polysulfate sodium - Drug Profile

Product Description

Mechanism Of Action

History of Events

Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile

Product Description

Mechanism Of Action

History of Events

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones

Featured News & Press Releases

Aug 08, 2022: MPS clinical program update and paradigm to present at the International Conference on lysosomal diseases

Jul 13, 2022: Paradigm partners with NFL Alumni Health on osteoarthritis program

Jul 06, 2022: Paradigm reports important global progress for the PARA_OA_002 phase 3 clinical trial evaluating Zilosul for osteoarthritis.

Jul 01, 2022: PARA_OA_008 study evaluating Zilosul mechanism and disease modifying effects completes recruitment

May 24, 2022: Paradigm Biopharmaceuticals spotlights potential breakthrough osteoarthritis treatment at Biological Association 3rd Annual Summit

May 05, 2022: Paradigm doses first subjects in Phase III knee osteoarthritis trial

Apr 13, 2022: FDA grants Fast Track Designation for Paradigm Biopharmaceuticals phase III osteoarthritis program

Mar 17, 2022: Paradigm Biopharmaceuticals initiates a phase 3 clinical trial in knee osteoarthritis across the U.S

Mar 17, 2022: Paradigm has received regulatory and ethics approvals for the PARA_OA_002 clinical trial in the UK.

Feb 11, 2022: International researchers highlight the need for PPS as a new adjunct therapy treatment for unmet needs of patients with MPS VI

Jan 13, 2022: First subjects randomised dosed in PARA_OA_002 phase 3 study in

Australia

Jan 12, 2022: Paradigm presentation at the 40th Annual J.P. Morgan Healthcare Conference

Dec 16, 2021: PPS treatment demonstrates improvement in heart function and tissue preservation in preclinical heart failure model

Nov 23, 2021: Positive interim data from phase 2 rare disease trial presented at international medical congress

Nov 03, 2021: Paradigm's Investigational New Drug (IND) application cleared by the US FDA.

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Aquilus Pharmaceuticals Inc, 2022
Pipeline by Avantyx Pharmaceuticals LLC, 2022
Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
Pipeline by Pharmahungary Group, 2022
Pipeline by SteroTherapeutics LLC, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CE4CF8E6D9D4EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CE4CF8E6D9D4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970